LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises
LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises
Read moreWed, 17th Apr 2013 07:20
LONDON MARKET PRE-OPEN: Barclays, AstraZeneca post sharp profit rises
Read more(Sharecast News) - Hikma Pharmaceutical said it made a good start to 2021 and that annual revenue from generic treatments would be at the top of guidance.
Read moreUK earnings, trading statements calendar - next 7 days
Read moreLONDON MARKET MIDDAY: Stocks recover modestly; Netflix misses targets
Read moreHikma resumes asthma drug launch, Vectura pays special dividend
Read moreLONDON MARKET OPEN: Stocks rise; Just Eat sinks on Germany competition
Read moreLONDON MARKET PRE-OPEN: Anto holds outlook, BHP cuts coal guidance
Read more(Sharecast News) - Hikma Pharmaceuticals has resumed the launch of its generic version of GlaxoSmithKline's 'Advair Diskus' in the United States, it announced on Wednesday, following Food and Drug Administration (FDA) approval of an amendment it submitted to its Abbreviated New Drug Application in January.
Read moreUK shareholder meetings calendar - next 7 days
Read moreLONDON MARKET CLOSE: Stocks end lower; investors shun Deliveroo
Read more(Sharecast News) - Hikma: Jefferies upgrades to buy with a target price of 2,870p.
Read moreLONDON MARKET MIDDAY: Biden spends big; Deliveroo dives on debut
Read more(Sharecast News) - Analysts at Jefferies upgraded drugmaker Hikma Pharmaceuticals from 'hold' to 'buy' on Wednesday, stating the group's share price was yet to reflect "a series of upcoming product catalysts".
Read moreBROKER RATINGS: BP cut by Morgan Stanley; Jefferies raises Hikma
Read more